CD30-Positive Lymphoma: Meaning and IHC Testing
Other names: CD30 positive
CD30 is an important marker in Hodgkin lymphoma and some T-cell lymphomas.
What does CD30-positive mean?
CD30 is a protein that may be found on some lymphoma cells. The result can help inform diagnosis and treatment planning, alongside the lymphoma type and full pathology report.
Source: NCI: CD30 protein
Prepare these details for your consultation
- Full pathology report and CD30 result
- Lymphoma type, stage and previous treatment
- Questions about options, availability and funding
The checklist is free, with no account or report upload. Navigator support is administrative; medical assessment and any service fees require separate confirmation.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
CD30 is a protein on the surface of some lymphoma cells. This examination helps confirm the type of lymphoma and may influence the choice of treatment category.
Clinical meaning
CD30 positivity opens up a category of specific antibody therapy in Hodgkin's lymphoma and some peripheral T-cell lymphomas as well as large cell anaplastic lymphoma.
Testing methods
- Immunohistochemistry (IHC)
A test that uses antibodies to mark specific proteins in tumour tissue.
- Tumour tissue biopsy
Collection of tumour tissue to confirm the diagnosis and provide material for further testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Pathology report stating CD30 positivity and its intensity.
- Correct classification of lymphoma according to pathology.
- Stage and history of previous therapy.
- Availability of drugs and financing requirements at the destination facility.
Related drugs
- Brentuximab vedotin
Anti-CD30 antibody-drug conjugate
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Guides discussing this marker
Written to help prepare questions and documents, not to replace a doctor's assessment.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NO DATA
No studies in the latest registry data mention this marker in their description.
Check options based on your result
Share the CD30 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Lymphoma
Cancer type
Reason: Related through a biomarker
- Immunotherapy
Treatment category
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Brentuximab vedotin
Drug
Reason: Targets this marker
- Reading a pathology report: which parts matter most
Guide
Reason: Related to this page
To check
- Tumour tissue biopsy
Diagnostic test
Reason: Diperiksa melalui
- Immunohistochemistry (IHC)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.